Zusammenfassung
Mehrere Interventionsstudien haben überzeugend demonstriert, daß die Gesamt- Morbidität und -Mortalität an kardiovaskulären Erkrankungen bei Patienten mit essentieller Hypertonie durch antihypertensive Therapie gesenkt werden kann [1–4]. Bei genauerer Analyse der Ergebnisse stellt sich aber heraus, daß Herzin-suffizienz, cerebrovaskuläre Ereignisse und Nierenversagen bei den aktiv behan-delten Patienten zwar signifikant weniger häufig auftreten, die Rate an Myo-kardinfarkten dagegen nicht abnimmt. Dies gilt insbesondere für Patienten bis zum 50. Lebensjahr [3].
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Literatur
McFate Smith W, Edlavitch SA, Krushat WM (1979) U. S. Public Health Service hospitals intervention trial in mild hypertension. In: Onesti G, Klimt CR (ed) Hypertension- determinants, complications and intervention. Grune and Straton, New York, p 381–399
Australian National Blood Pressure Study Management Committee. The Australian therapeutic trial in mild hypertension. (1980) Lancet 1: 1261–1267
Hypertension Detection and Follow-up Program Cooperative Group. (1979) Five-year findings of the hypertension detection and follow-up program. (1) Reduction in mortality of persons with high blood pressure, including mild hypertension. (2) Mortality by race, sex and age. Jama 242: 2562–2577
Helgeland A (1980) Treatment of mild hypertension: A five-year controlled drug trial. The Oslo study. Am J Med 69: 725–732
Lowenstein J, Neusy AJ (1982) The biochemical effects of antihypertensive agents and the impact on atherosclerosis. J Cardiovasc Pharmacol 4 Suppl 2: 262–264
Day JL, Simpson N, Metcalfe J et al (1979) Metabolic consequences of atenolol and propranolol in treatment of essential hypertension. Br Med J 1: 77–80
Tanaka N, Sakaguchi S, Oshige K et al (1976) Effect of chronic administration of propranolol on lipoprotein composition. Metabolism 25: 1071–1075
Kristensen BØ (1981) Effect of long-term treatment with beta-blocking drugs on plasma lipids and lipoproteins. Br Med J 283: 191–192
Lehtonen A, Viikari J (1979) Long-term effect of Sotalol on plasma lipids. Clin Sci 57: 405s–407s
Bielmann P, Leduc G, Davignon J (1980) Bêta-bloquants sélectif (métoprolol) vs non- sélectif (propranolol) Effets comparés sur la composition des lipoprotéines plasmatiques et la pression sanguine. Union Med Can 109: 1734–1740
Schauer I, Schauer U, Ruhling K et al (1980) The effect of propranolol treatment on total cholesterol, HDL cholesterol, triglycerides, postheparin lipolytic activity and lecithin: Cholesterol acyltransferase in hypertensive individuals. Artery 8: 146–150
Leren P, Foss OP, Helgeland A etal (1981) Effects of pindolol and hydrochlorothiazide on blood lipids. The Oslo Study. Clin Trials J 18: 254–261
Leren P, Helgeland A, Holme I, Foss OP, Hjermann I, Lund-Larsen PG (1980) Effect of propranolol and prazosin on blood lipids. The Oslo Study. Lancet 11: 4–6
England JDF, Simons LA, Gibson JC, et al (1980) The effect of metoprolol and atenolol on plasma high density lipoprotein levels in man. Clin Exp Pharmacol Physiol 7: 329–333
Ballantyne D, Ballantyne FC, McMurdo (1981) Effect of slow Oxprenolol and a combination of slow Oxprenolol and cyclopenthiazide on plasma lipoproteins. Atherosclerosis 39: 301–306
Eliasson K, Lis LE, Rössner S (1981) Serum lipoprotein changes during atenolol treatment of essential hypertension. Eur J Clin Pharmacol 20: 335–338
Ames RP, Hill P (1976) Increase in serum-lipids during treatment of hypertension with chlorthalidone. Lancet 1: 721–723
Gluck Z, Weidmann P, Mordasini R, et al (1979) Einfluß einer Diuretikatherapie auf die Serumlipoproteine: Ein unerwünschter Effekt? Schweiz Med Wochenschr 109: 104–108
Goldman AI, Steele BW, Schnaper HW, et al (1980) Serum lipoprotein levels during chlorthalidone therapy. Jama 244: 1691–1695
Joos C, Kewitz H, Reinhold-Kourniati D (1980) Effects of diuretics on plasma lipoproteins in healthy men. Eur J Clin Pharmacol 17: 251–257
Ames RP, Hill P (1982) Improvement of glucose tolerance and lowering of glycohemoglobin and serum lipid concentrations after discontinuation of antihypertensive drug therapy. Circulation 65: 899–904
Röschlau P, Berat E, Gruber W (1974) Enzymatische Bestimmung des Gesamt-Cholesterin im Serum. Z Klin Chem Klin Biochem 12: 403–407
Bucolo G, David H (1973) Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem 19: 476–482
Wieland H, Scidel D (1978) Fortschritte in der Analytik des Lipoproteinmusters. Innere Medizin 7: 290–300
Myers LH, Phillips NR, Havel RJ (1976) Mathematical evaluation of methods for estimation of the concentration of the major lipid components of human serum lipoproteins. J Lab Clin Med 88: 491–505
Schonfeld G, Bailey A, Steelman R (1978) Plasma apolipoproteins, A-I and A-II levels in hyperlipidemia. Lipids 13: 951–959
Ames RP, Hill P (1978) Raised serum lipid concentrations during diuretic treatment of hypertension: a study of predictive indexes. Clin Sci Mol Med 55: 311s–314s
Abraham CE, Huff TA, Cope ND, Wilson JB, Bransome ED, Huisman JHT (1978) Determination of the glycosylated hemoglobin ( Hb AI) with a new microcolumn procedure. Diabetes 27: 931
Day JL, Metcalfe J, Simpson CN (1982) Adrenergic mechanisms in control of plasma lipid concentrations. Br Med J 284: 1145–1148
Eisenberg S, Patsch JR, Olivecrona T, Gotto AM (1978) Effects of lipolysis on human lipid density lipoproteins (HDL). Circulation 58: suppl abstract 47
Tall AR, Small DM (1978) Plasma high density lipoproteins. N Engl J Med 299:1232– 1236
McGonigle RJS, Williams L, Murphy MJ, Parsans V (1981) Labetalol and lipids. Lancet 1: 163
Hulley SB, Rosenman RN, Bawol RD, etal (1980) Epidemiology as a guide to clinical decisions. The association between triglyceride and coronary heart disease. N Engl J Med 302: 1383–1389
Böttcher CJF, Boelsma-van Houte E, Romeny-Wachter CC, Woodford FP, van Gent CM (1960) Lipid and fatty-acid composition of coronary and cerebral arteries at different stages of atherosclerosis. Lancet 2:1162–1166
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1984 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Stumpe, K.O., Müller, H.M., Klautke, G., Overlack, A., Kolloch, R. (1984). Betablocker versus Diuretika in der antihypertensiven Therapie: Beeinflussung des Lipid- und Glukosestoffwechsels. In: Schettler, G., Assmann, G., Diehm, C., Moerchel, J. (eds) Betablocker und Lipidstoffwechsel. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-69675-6_18
Download citation
DOI: https://doi.org/10.1007/978-3-642-69675-6_18
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-69676-3
Online ISBN: 978-3-642-69675-6
eBook Packages: Springer Book Archive